Dawn S. Chandler
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
92
Citations
2,108
Est. group size
~3
Recurring co-author estimate
Active years
33
Publishing since 1994
Dawn S. Chandler studies how genes are alternatively spliced (a process where cells cut and rearrange gene messages to make different protein versions) in cancers, especially sarcomas like liposarcoma and osteosarcoma. Her work focuses on how splicing of genes such as MDM2, MDM4, and the insulin receptor affects the tumor-suppressor protein p53 and other cancer-related pathways, and she explores splice-switching oligonucleotides (lab-made molecules that can redirect splicing) as potential therapies.
Publication output was modest and fairly steady from 2017-2022, spiked sharply in 2023 (likely due to a cluster of related supplementary materials/data records), and has since declined to a lower, still active rate through 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Conserved sequence elements in the final exon of MDM2-eight-exon skipping event reveal a ‘cassette regulon’ model of alternative splicing controlled by a distal regulatory element
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Abstract 5999: Therapeutic delivery of splice switching oligonucleotides to restore p53 function in liposarcoma
Cancer Research · 2025
- Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing
PLoS ONE · 2025
- Employing splice-switching oligonucleotides and AAVrh74.U7 snRNA to target insulin receptor splicing and cancer hallmarks in osteosarcoma
Molecular Therapy Oncology · 2024
- Oncogenic Functions of Alternatively Spliced MDM2-ALT2 Isoform in Retroperitoneal Liposarcoma
International Journal of Molecular Sciences · 2024
- Progress in sarcomas: Highlights from the 2023 annual meeting of the Connective Tissue Oncology Society
Molecular Therapy Oncology · 2024
- Blockade of Interleukin-6 (IL-6) Signaling in Dedifferentiated Liposarcoma (DDLPS) Decreases Mouse Double Minute 2 (MDM2) Oncogenicity via Alternative Splicing
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Abstract A054: Oncogenic functions of alternatively spliced <i>MDM2-ALT2</i> isoform in retroperitoneal liposarcoma
Clinical Cancer Research · 2024
- Data from Genotoxic Stress Induces Coordinately Regulated Alternative Splicing of the p53 Modulators MDM2 and MDM4
2023
- Supplementary Figure 1 from Genotoxic Stress Induces Coordinately Regulated Alternative Splicing of the p53 Modulators MDM2 and MDM4
2023
- Supplementary Figure 1 from Genotoxic Stress Induces Coordinately Regulated Alternative Splicing of the p53 Modulators MDM2 and MDM4
2023
- Data from Genotoxic Stress Induces Coordinately Regulated Alternative Splicing of the p53 Modulators MDM2 and MDM4
2023
- Video 3 from <i>DEAR1</i> Is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-β–Driven Epithelial–Mesenchymal Transition
2023
- Video 1 from <i>DEAR1</i> Is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-β–Driven Epithelial–Mesenchymal Transition
2023
- Data from <i>DEAR1</i> Is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-β–Driven Epithelial–Mesenchymal Transition
2023
- Cancer Research×10
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Molecular Therapy Oncology×2
- Human Genetics×2
- Trends in Genetics×1
- Jill L. Reiter
Biochemistry, Genetics and Molecular Biology · Indiana University
- Lauren A. Woodward
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Caleb M. Embree
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Daniel H. Kim
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Maria C. Sterrett
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile